Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 15;10:763. doi: 10.3389/fonc.2020.00763

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Sundar, Smyth, Peng, Yeong and Tan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. PD-L1 expression can be measured in the form of Combined Positive Score (CPS) has been shown to predict response to anti-PD1 or anti-PD-L1 therapies (1). Microsatellite Instability (MSI) leads to a large number of somatic mutations and production of neoantigens. MSI is one of the most common causes of high Tumor Mutational Burden (TMB) (2). EBV associated Gastric Cancer (EBVaGC) has been postulated to be sensitive to ICI due to high intra-tumoral immune infiltration and expression of PD-L1 and PD-L2 (3). Various gene signatures have been developed to identify genes that can predict response to ICI (4). Combination of HER-2 and anti-PD1 therapy enhance antibody-dependent cellular cytotoxicity leading to improved outcomes with ICI (5).